ALEXION PHARMACEUTICALS, INC. (NASDAQ:ALXN) Files An 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued
Listing Rule or Standard; Transfer of Listing.
received a notice from The NASDAQ Stock Market (NASDAQ) stating
that Alexion is not in compliance with NASDAQ Marketplace Rule
5250(c)(1) because Alexion has not timely filed its Quarterly
Report on Form 10-Q for the fiscal quarter ended September 30,
2016 (the Quarterly Report). The NASDAQ notice has no immediate
effect on the listing of Alexions common stock on the NASDAQ
Global Select Market.
2017 to either file the Quarterly Report or submit a plan of
compliance to NASDAQ to address any issues it believes would
support its request for an extension of time to regain compliance
with NASDAQ continued listing requirements of up to 180 calendar
days from the due date of the Quarterly Report. If Alexion is
unable to file the Quarterly Report by January 17, 2017, it
intends to submit a plan of compliance on or prior to that date.
Alexion intends to take all necessary steps to achieve compliance
with NASDAQ continued listing requirements.
receipt of the notice. A copy of such press release is attached
as Exhibit 99.1 hereto.
|
99.1
|
Press release dated November 16, 2016.
|
About ALEXION PHARMACEUTICALS, INC. (NASDAQ:ALXN)
Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. The Company operates through innovation, development and commercialization of life-transforming therapeutic products segment. The Company’s marketed products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical programs include Soliris (eculizumab), ALXN 1101, ALXN 1007, SBC-103, ALXN 1210 and ALXN 5500. It offers Soliris for patients with either paroxysmal nocturnal hemoglobinuria (PNH), a life-threatening and ultra-rare genetic blood disorder, or atypical hemolytic uremic syndrome (aHUS), a life-threatening and ultra-rare genetic disease. Strensiq is a targeted enzyme replacement therapy. It offers Kanuma for the treatment of patients with Lysosomal Acid Lipase Deficiency (LAL-D). ALXN 1007 is a humanized antibody designed to target inflammatory disorders. ALEXION PHARMACEUTICALS, INC. (NASDAQ:ALXN) Recent Trading Information
ALEXION PHARMACEUTICALS, INC. (NASDAQ:ALXN) closed its last trading session up +2.15 at 122.51 with – shares trading hands.
